A comprehensive review of post-market clinical studies performed in adults with an Asian probiotic formulation

Benef Microbes. 2010 Mar;1(1):93-106. doi: 10.3920/BM2008.1005.


Probiotics as dietary supplements have been readily accepted by Asian populations. Use of certain probiotic preparations is widespread and the number of clinical trials undertaken with such products is unparalleled in western scientific literature. One such preparation, containing a combination of Enterococcus faecium R0026 and Bacillus subtilis R0179, has 23 publications on post-market clinical studies involving over 1,800 adults. The majority of these publications are printed in Chinese and Korean journals. This review examines the clinical findings with this probiotic combination. As mono-therapy, it has been used to overcome symptoms associated with chronic diarrhoea and irritable bowel syndrome. It has been used as co-adjuvant therapy with sulfasalazine and mesalazine to improve remission times in mild to moderate Ulcerative Colitis and to improve compliance with conventional triple therapy for Helicobacter pylori eradication. While the much of the data is preliminary and the study designs require refinement, the contribution of these trials should not be ignored. The information derived in this review will provide practitioners with practical information on appropriate applications for probiotic supplements, expected outcomes, dosing regimes, safety and reported adverse events. Furthermore, identification of problems in these trials should help researchers design better clinical trials when investigating probiotic products.

Publication types

  • Review

MeSH terms

  • Adult
  • Animals
  • Asia
  • Clinical Trials as Topic
  • Female
  • Gastrointestinal Diseases / drug therapy*
  • Gastrointestinal Diseases / microbiology
  • Humans
  • Male
  • Probiotics / therapeutic use*
  • Product Surveillance, Postmarketing*